|1.||Liu, Bin: 9 articles (03/2015 - 01/2013)|
|2.||Liu, Jie: 9 articles (03/2015 - 01/2013)|
|3.||Zhu, Runzhi: 8 articles (03/2015 - 01/2013)|
|4.||Zhang, Qingyu: 8 articles (03/2015 - 01/2013)|
|5.||Li, Mingyi: 7 articles (03/2015 - 01/2013)|
|6.||Mi, Mantian: 3 articles (11/2015 - 07/2015)|
|7.||Zhu, Jundong: 3 articles (11/2015 - 07/2015)|
|8.||Zhang, Qianyong: 3 articles (11/2015 - 07/2015)|
|9.||Wu, Shixing: 3 articles (01/2015 - 01/2013)|
|10.||Liang, Jian: 3 articles (01/2015 - 01/2014)|
|1.||Osteosarcoma (Osteogenic Sarcoma)
09/01/2014 - "The present study examined the antitumor activity both in vitro and in vivo without noticeable side effects and the underlying mechanism of action of dihydromyricetin in osteosarcoma cells. "
09/01/2014 - "In conclusion, our results are the first to suggest that dihydromyricetin may be a therapeutic candidate for the treatment of osteosarcoma."
09/01/2014 - "We found that dihydromyricetin induced increased p21 expression and G2-M cell-cycle arrest, caused DNA damage, activated ATM-CHK2-H2AX signaling pathways, and induced apoptosis in osteosarcoma cells as well as decreasing the sphere formation capability by downregulating Sox2 expression. "
09/01/2014 - "Finally, immunohistochemical analysis indicated that some patients had a lower p-AMPK expression after chemotherapy, which supports that the combination of dihydromyricetin and chemotherapy drug will be beneficial for patients with osteosarcoma. "
09/01/2014 - "Mechanistic analysis showed that the antitumor potential of dihydromyricetin may be due to the activation of AMPKα and p38(MAPK), as the activating AMPKα led to the inactivation of GSK3β in osteosarcoma cells. "
07/05/2015 - "Dihydromyricetin improves skeletal muscle insulin resistance by inducing autophagy via the AMPK signaling pathway."
09/01/2015 - "We conclude that dihydromyricetin supplementation improves glucose and lipid metabolism as well as various biochemical parameters in patients with nonalcoholic fatty liver disease, and the therapeutic effects of dihydromyricetin are likely attributable to improved insulin resistance and decreases in the serum levels of tumor necrosis factor-alpha, cytokeratin-18, and fibroblast growth factor 21."
09/01/2015 - "The serum levels of alanine, aspartate aminotransferase, γ-glutamyl transpeptidase, glucose, low-density lipoprotein-cholesterol and apolipoprotein B, and the homeostasis model assessment of insulin resistance (HOMA-IR) index were significantly decreased in the dihydromyricetin group compared with the placebo group. "
|3.||Alzheimer Disease (Alzheimer's Disease)
|4.||Hepatocellular Carcinoma (Hepatoma)
08/07/2014 - "Dihydromyricetin inhibits migration and invasion of hepatoma cells through regulation of MMP-9 expression."
01/01/2014 - "We assessed the effects of dihydromyricetin (DHM) on the induction of ROS accumulation and on the activation of the mitochondrial signaling pathway in human hepatoma HepG2 cells. "
01/01/2014 - "Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism."
11/01/2013 - "Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway."
01/01/2013 - "Dihydromyricetin reduced Bcl-2 expression via p53 in human hepatoma HepG2 cells."
11/01/2015 - "Dihydromyricetin (DHM) is a natural flavonol which provides a wide range of health benefits including anti-inflammatory and anti-tumor effects. "
04/01/2014 - "Dihydromyricetin (DHM), a bioactive flavonoid compound extracted from the stems and leaves of Ampelopsis grossedentata, has oxidation resistance, anti-tumor and free radical scavenging capabilities. "
10/01/2012 - "Probing the interaction of anti-cancer agent dihydromyricetin with human serum albumin: a typical method study."
06/11/2015 - "Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives."
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||Keratin-18 (Keratin 18)
|4.||Non-alcoholic Fatty Liver Disease
|5.||fibroblast growth factor 21
|6.||NF-kappa B (NF-kB)
|9.||Reactive Oxygen Species (Oxygen Radicals)
|10.||AMP-Activated Protein Kinases
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)